These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12724497)

  • 21. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe tremors associated with use of thalidomide.
    Chiruka S; Chapman CS
    Am J Hematol; 2005 Jan; 78(1):81-2. PubMed ID: 15609275
    [No Abstract]   [Full Text] [Related]  

  • 23. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
    J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thalidomide in oncological and hematological diseases].
    Kivivuori SM; Anttila P
    Duodecim; 2010; 126(12):1413-9. PubMed ID: 20617746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
    Go RS; Horstman AL
    Clin Cancer Res; 2002 Aug; 8(8):2750; author reply 2751. PubMed ID: 12171909
    [No Abstract]   [Full Text] [Related]  

  • 26. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
    Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
    Zangari M; Barlogie B; Anaissie E; Saghafifar F; Eddlemon P; Jacobson J; Lee CK; Thertulien R; Talamo G; Thomas T; Van Rhee F; Fassas A; Fink L; Tricot G
    Br J Haematol; 2004 Sep; 126(5):715-21. PubMed ID: 15327525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalidomide-induced pneumonitis.
    Wyplosz B; Lerolle U; Israël-Biet D; Dougados J; Lillo-Le Louët A; Ghez D; Pouchot J
    Eur J Intern Med; 2008 Nov; 19(7):e57-8. PubMed ID: 19013366
    [No Abstract]   [Full Text] [Related]  

  • 30. Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.
    Magalini F; Stella A; Sansoni P
    Intern Emerg Med; 2008 Dec; 3(4):383-5. PubMed ID: 18320148
    [No Abstract]   [Full Text] [Related]  

  • 31. Venous sinus thrombosis in a patient taking thalidomide.
    Lenz RA; Saver J
    Cerebrovasc Dis; 2004; 18(2):175-7. PubMed ID: 15256794
    [No Abstract]   [Full Text] [Related]  

  • 32. [Desensitization to lenalidomide].
    Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME
    Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448
    [No Abstract]   [Full Text] [Related]  

  • 33. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
    Wang M; Liu Y; Li Y; Wu H
    Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.
    Antonioli E; Nozzoli C; Gianfaldoni G; Mannelli F; Rossi S; Betti S; Bernardeschi P; Fiorentini G; Bosi A
    Ann Oncol; 2005 Nov; 16(11):1849-50. PubMed ID: 16012178
    [No Abstract]   [Full Text] [Related]  

  • 35. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt.
    Santos AB; Llamas P; Román A; Prieto E; De Oña R; De Velasco JF; Tomás JF
    Br J Haematol; 2003 Jul; 122(1):159-60. PubMed ID: 12823358
    [No Abstract]   [Full Text] [Related]  

  • 38. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
    Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thalidomide-induced organizing pneumonia.
    Feaver AA; McCune DE; Mysliwiec AG; Mysliwiec V
    South Med J; 2006 Nov; 99(11):1292-4. PubMed ID: 17195429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose of thalidomide in the treatment of refractory myeloma.
    Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A
    Haematologica; 2000 Oct; 85(10):1111-2. PubMed ID: 11025615
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.